- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04816890
A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)
A Phase 2 Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in T1DM Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After a run in period in case of basal insulin switch or Continuous Glucose Monitoring (CGM) initiation, eligible subjects will enter a 3 weeks baseline recording period.
Subjects will then be randomized to either M1 Pram P037 treatment or active comparator treatment (insulin lispro). Both investigator and enrolled subjects will be unblinded to treatment. Study participants will use CGM until follow-up visit.
Treatment period will last 16 weeks. Throughout the 4-month treatment period, basal insulin and investigational products administration will be individually adjusted. Treatment Satisfaction Questionnaire and WHO-5 well-being index will be completed by subjects at day 0 and after 2 months (Visit 9) and 4 months (Visit 11) of treatment.
A safety follow-up visit, 7 to 14 days after the last administration of IMP, will mark the end of the clinical trial for the subjects.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Mainz, Germany, 55116
- Profil Mainz GmbH & Co
-
Neuss, Germany, 41460
- Profil Institut für Stoffwechselforschung GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated informed consent obtained before any trial-related activities. Trial-related activities are any procedures that would not have been done during normal management of the subject.
- Subjects with type 1 diabetes mellitus.
- Body Mass Index (BMI) between 25.0 and 35.0 kg/m^2, both inclusive.
- HbA1c between 7.0 % and 9.5 %, both inclusive.
- Diabetes duration of at least 12 months.
- Using a multiple dosing insulin therapy (MDI) with a basal insulin and a rapid-acting insulin at at least two meals per day.
- Using any CGM or Flash Glucose Monitoring (FGM) for at least 1 month or willing to use CGM during the trial.
Exclusion Criteria:
- Known or suspected hypersensitivity to IMPs or any of the excipients or to any component of the IMP formulation.
- Type 2 diabetes mellitus.
- Receipt of any medicinal product in clinical development within 3 months or at least 5 half-lives of the related substances and their metabolites (whichever is longer) before randomisation in this trial.
- History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
- Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer as judged by the Investigator.
- Clinically significant abnormal screening laboratory tests, as judged by the Investigator.
- Systolic blood pressure < 90 mmHg or >139 mmHg and/or diastolic blood pressure < 50 mmHg or > 89 mmHg. One repeat test (on a different day, if necessary) will be acceptable in case of suspected white-coat hypertension.
- Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position at screening, as judged by the Investigator.
- Proliferative retinopathy or maculopathy as judged by the Investigator based on a recent (<1.5 years) ophthalmologic examination.
- Severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator.
- More than one episode of severe hypoglycaemia with seizure, coma or requiring assistance of another person during the past 6 months.
- Hypoglycaemic unawareness as judged by the Investigator.
- Hospitalisation for diabetic ketoacidosis during the previous 6 months.
- Presence of clinically significant gastrointestinal symptoms (e.g., nausea, vomiting, heartburn or diarrhea), as judged by the Investigator.
- Confirmed diagnosis of gastroparesis or requiring the use of drugs that alter gastrointestinal motility.
- Unusual meal habits and special diet requirements that could constitute a risk for the subject when participating in the trial or interfere with the interpretation of data.
- Use of oral antidiabetic drugs (OADs) and/or GLP-1 receptor agonists within 4 weeks prior to screening.
- Use of systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra-articular, or inhaled preparations) within 2 months prior to screening.
- Use or planned use of drugs that promote weight loss (e.g. liraglutide, semaglutide, orlistat, lorcaserin, phentermine) within 2 months prior to screening.
- If female, pregnancy or breast-feeding.
- Women of childbearing potential who are not using a highly effective contraceptive method.
- The Investigator considers a subject as unsuitable for inclusion in the study for any other reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: M1 Pram P037
Multi daily administration of M1 Pram P037 by subcutaneous injection
|
Subcutaneous administration of M1 Pram P037 in combination with a basal insulin.
|
ACTIVE_COMPARATOR: Insulin lispro
Multi daily administration of insulin lispro (Humalog®) by subcutaneous injection
|
Subcutaneous administration of insulin lispro in combination with a basal insulin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body weight change from baseline to week 16 of treatment
Time Frame: From week 0 to week 16
|
Change in body weight after 16 weeks of treatment
|
From week 0 to week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TIR [70-180] mg/dL.
Time Frame: From week 0 to week 16
|
Time In Range [70-180] mg/dL change from baseline to week 16 of treatment as measured by CGM.
|
From week 0 to week 16
|
%TIR [70-180] mg/dL.
Time Frame: From week 0 to week 16
|
Percentage of Time In Range [70-180] mg/dL change from baseline to week 16 of treatment as measured by CGM.
|
From week 0 to week 16
|
TIR [70-140] mg/dL.
Time Frame: From week 0 to week 16
|
Time In Range [70-140] mg/dL change from baseline to week 16 of treatment as measured by CGM.
|
From week 0 to week 16
|
%TIR [70-140] mg/dL.
Time Frame: From week 0 to week 16
|
Percentage of Time In Range [70-140] mg/dL change from baseline to week 16 of treatment as measured by CGM.
|
From week 0 to week 16
|
MeanG_24h
Time Frame: From week 0 to week 16
|
Average glucose over 24h change from baseline to week 16 of treatment
|
From week 0 to week 16
|
CVG_24h
Time Frame: From week 0 to week 16
|
Coefficient Of Variation of glucose over 24h change from baseline to week 16 of treatment.
|
From week 0 to week 16
|
DistG_24h
Time Frame: From week 0 to week 16
|
Distance travelled over 24h change from baseline to week 16 of treatment
|
From week 0 to week 16
|
SDG_24h
Time Frame: From week 0 to week 16
|
Standard Deviation of all glucose values over 24h change from baseline to week 16 of treatment
|
From week 0 to week 16
|
HbA1c
Time Frame: From week 0 to week 16
|
HbA1c change from baseline to week 16 of treatment
|
From week 0 to week 16
|
Total Insulin doses
Time Frame: From week 0 to week 16
|
Change from baseline of total insulin doses
|
From week 0 to week 16
|
Prandial Insulin doses
Time Frame: From week 0 to week 16
|
Change from baseline of prandial (per meal), insulin doses
|
From week 0 to week 16
|
Basal Insulin doses
Time Frame: From week 0 to week 16
|
Change from baseline of basal insulin doses
|
From week 0 to week 16
|
Number of Adverse Events
Time Frame: From week 0 to week 16
|
Number of Adverse Events observed during the treatment period
|
From week 0 to week 16
|
Duration of Adverse Events
Time Frame: From week 0 to week 16
|
Duration of Adverse Events observed during the treatment period
|
From week 0 to week 16
|
Hypoglycaemic episodes
Time Frame: From week 0 to week 16
|
Number of Hypoglycemic episodes during the 16 weeks treatment period
|
From week 0 to week 16
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eugen Baumgaertner, MD, Profil Institut für Stoffwechselforschung GmbH
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT041-ADO09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
Clinical Trials on M1 Pram P037
-
The Hong Kong Polytechnic UniversityNot yet recruitingChronic Pain | Insomnia
-
Guangzhou Virotech Pharmaceutical Co., Ltd.Not yet recruiting
-
Sheba Medical CenterSuspended
-
Samsung Medical CenterCompletedStroke | Motor Disorder
-
University of OxfordCompletedSeasonal InfluenzaUnited Kingdom
-
Beijing HospitalUnknownCerebrovascular DiseaseChina
-
The Cleveland ClinicCompletedCardiovascular Diseases | Vascular Diseases | Stroke | Cerebrovascular Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System DiseasesUnited States
-
Cardarelli HospitalUnknownPain | Bladder Cancer | LUTS
-
European Vaccine InitiativeUniversity of Oxford; Malaria Research and Training Center, Bamako, MaliNot yet recruitingHealthy Women of Child Bearing Potential
-
Hospital de Clinicas de Porto AlegreCompletedPain | Working Memory | Transcranial Direct Current StimulationBrazil